Pregled bibliografske jedinice broj: 14204
Novel hybrid polyketide therapeutics made by metabolic engineering
Novel hybrid polyketide therapeutics made by metabolic engineering // 1. skup Hrvatskog društva za biotehnologiju, Program rada i zbornik sažetaka / Kniewald, Z. (ur.).
Zagreb: Hrvatsko Društvo za Biotehnologiju, 1998. (pozvano predavanje, domaća recenzija, sažetak, pregledni)
CROSBI ID: 14204 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Novel hybrid polyketide therapeutics made by metabolic engineering
Autori
Hranueli, Daslav
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, pregledni
Izvornik
1. skup Hrvatskog društva za biotehnologiju, Program rada i zbornik sažetaka
/ Kniewald, Z. - Zagreb : Hrvatsko Društvo za Biotehnologiju, 1998
Skup
1. skup Hrvatskog društva za biotehnologiju
Mjesto i datum
Zagreb, Hrvatska, 19.02.1998. - 20.02.1998
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Streptomyces; polyketide; novel chemical entities
Sažetak
Streptomyces species have enormous potential for the biosynthesis of chemically diverse polyketide structures with a broad spectrum of biological activities (Nisbet, Ciba Symp., 171: 215, 1992). For that reason this project aims to construct genetically modified strains of Streptomyces rimosus capable of generating novel chemical entities of potential therapeutic value which are based on the carbon skeleton of aromatic polyketide antibiotic oxytetracycline (OTC). This species has been already used in Croatia for a long time to make OTC (e.g. Hranueli et al., Food Technol. Biotechnol. Rev., 33: 51, 1995). Our understanding of biosynthesis of bioactive metabolites by streptomycetes has recently improved substantially, especially the generation of novel therapeutics by this route is a viable proposition (Khosla & Zawada, Trends Biotechnol., 14: 335 1996). During the proposed research, some otc genes of S. rimosus will be inactivated by homologous recombination and replaced by heterologous genes from other streptomycetes that synthesise related but chemically different polyketide structures. It is expected that the constructed strains will be capable of biosynthesising novel, 'hybrid', chemical entities. Novel hybrid products will be isolated, characterised chemically and screened for biological activities that could form the basis of new therapeutics. For the efficient construction of genetically modified strains of S. rimosus, further analysis of its genome structure and stability are planed. Besides, we started the study of S. rimosus physiology and its behaviour in biotechnological processes as well as the study of specificity and kinetics of enzymes involved in OTC resistance, by studying enzyme/substrate crystal complexes, including their ability to accept novel substrates.
Izvorni jezik
Engleski
Znanstvena područja
Prehrambena tehnologija
POVEZANOST RADA
Projekti:
058407
Ustanove:
Prehrambeno-biotehnološki fakultet, Zagreb
Profili:
Daslav Hranueli
(autor)